mtDNA Copy Number Research Articles

High heteroplasmy is associated with low mitochondrial copy number and selection against non-synonymous mutations in the snail Cepaea nemoralis

Molluscan mitochondrial genomes are unusual because they show wide variation in size, radical genome rearrangements and frequently show high variation (> 10%) within species. As progress in understanding this variation has been limited, we used whole genome sequencing of a six-generation matriline of the terrestrial snail Cepaea nemoralis, as well as whole genome sequences from wild-collected C. nemoralis, the sister species C. hortensis, and multiple other snail species to explore the origins of mitochondrial DNA (mtDNA) variation. The main finding is that a high rate of SNP heteroplasmy in somatic tissue was negatively correlated with mtDNA copy number in both Cepaea species. In individuals with under ten mtDNA copies per nuclear genome, more than 10% of all positions were heteroplasmic, with evidence for transmission of this heteroplasmy through the germline. Further analyses showed evidence for purifying selection acting on non-synonymous mutations, even at low frequency of the rare allele, especially in cytochrome oxidase subunit 1 and cytochrome b. The mtDNA of some individuals of Cepaea nemoralis contained a length heteroplasmy, including up to 12 direct repeat copies of tRNA-Val, with 24 copies in another snail, Candidula rugosiuscula, and repeats of tRNA-Thr in C. hortensis. These repeats likely arise due to error prone replication but are not correlated with mitochondrial copy number in C. nemoralis. Overall, the findings provide key insights into mechanisms of replication, mutation and evolution in molluscan mtDNA, and so will inform wider studies on the biology and evolution of mtDNA across animal phyla.

A method for measuring mitochondrial DNA copy number in pediatric populations

The mitochondrion is a multifunctional organelle that modulates multiple systems critical for homeostasis during pathophysiological stress. Variation in mitochondrial DNA (mtDNA) copy number (mtDNAcn), a key mitochondrial change associated with chronic stress, is an emerging biomarker for disease pathology and progression. mtDNAcn can be quantified from whole blood samples using qPCR to determine the ratio of mtDNA to nuclear DNA. However, the collection of blood samples in pediatric populations, particularly in infants and young children, can be technically challenging, yield much smaller volume samples, and can be distressing for the patients and their caregivers. Therefore, we have validated a mtDNAcn assay utilizing DNA from simple buccal swabs (Isohelix SK-2S) and report here it's performance in specimens from infants (age = <12 months). Utilizing qPCR to amplify ∼200 bp regions from two mitochondrial (ND1, ND6) and two nuclear (BECN1, NEB) genes, we demonstrated absolute (100%) concordance with results from low-pass whole genome sequencing (lpWGS). We believe that this method overcomes key obstacles to measuring mtDNAcn in pediatric populations and creates the possibility for development of clinical assays to measure mitochondrial change during pathophysiological stress.

Protective effect of melatonin against methamphetamine-induced attention deficits through miR-181/SIRT1 axis in the prefrontal cortex.

Methamphetamine (METH) is an addictive psychostimulant with deleterious effects on the central nervous system. Chronic use of METH in high doses impairs cognition, attention and executive functions, but the underlying mechanisms are still unclear. Sirtuin 1 (SIRT1) is a post-translational regulator that is downregulated following METH neurotoxicity. Melatonin is a neuroprotective hormone that enhances mitochondrial metabolism. Here, we evaluated the effect of melatonin on METH-induced attention deficits disorder and the involvement of the miR-181/SIRT1 axis in melatonin neuroprotection. METH at a dose of 5mg/kg was injected for 21 consecutive days. The animals were assigned to receive either melatonin or the vehicle after METH injections. Attention levels were evaluated with abject-based attention test. In the prefrontal cortex, the expression levels of miR-181a-5p, SIRT1, p53 and CCAR2, as well as the mtDNA copy numbers were evaluated using qRT-PCR and western blotting. The outcomes revealed that melatonin treatment following METH injections improved METH-induced attention deficits. METH toxicity can be associated with changes in the miR-181/SIRT1 axis, elevated levels of p53 and COXII, and decreased levels of mtDNA in the prefrontal cortex of adult rats. Interestingly, administration of melatonin can improve the expression of these molecules and reduces the toxic effects of METH. Melatonin ameliorated the neurotoxicity of METH in the prefrontal cortex and the miR-181/SIRT1 axis is involve in the protective effects of melatonin. However, melatonin can be potentially administrated to improve attention impairment in METH use disorders.

Disrupted mitochondrial transcription factor A expression promotes mitochondrial dysfunction and enhances ocular surface inflammation by activating the absent in melanoma 2 inflammasome

PurposeSevere dry eye disease causes ocular surface damage, which is highly associated with mitochondrial dysfunction. Mitochondrial transcription factor A (TFAM) is essential for packaging mitochondrial DNA (mtDNA) and is crucial for maintaining mitochondrial function. Herein, we aimed to explore the effect of a decreased TFAM expression on ocular surface damage. MethodsFemale C57BL/6 mice were induced ocular surface injury by topical administrating benzalkonium chloride (BAC). Immortalized human corneal epithelial cells (HCECs) were stimulated by tert-butyl hydroperoxide (t-BHP) to create oxidative stress damage. HCECs with TFAM knockdown were established. RNA sequencing was employed to analyze the whole-genome expression. Mitochondrial changes were measured by transmission electron microscopy, Seahorse metabolic flux analysis, mitochondrial membrane potential, and mtDNA copy number. TFAM expression and inflammatory cytokines were determined using RT-qPCR, immunohistochemistry, immunofluorescence, and immunoblotting. ResultsIn both the corneas of BAC-treated mice and t-BHP-induced HCECs, we observed impaired TFAM expression, accompanied by mitochondrial structure and function defects. TFAM downregulation in HCECs suppressed mitochondrial respiratory capacity, reduced mtDNA content, induced mtDNA leakage into the cytoplasm, and led to inflammation. RNA sequencing revealed the absent in melanoma 2 (AIM2) inflammasome was activated in the corneas of BAC-treated mice. The AIM2 inflammasome activation was confirmed in TFAM knockdown HCECs. TFAM knockdown in t-BHP-stimulated HCECs aggravated mitochondrial dysfunction and the AIM2 inflammasome activation, thereby further triggering the secretion of inflammatory factors such as interleukin (IL) -1β and IL-18. ConclusionsTFAM reduction impaired mitochondrial function, activated AIM2 inflammasome and promoted ocular surface inflammation, revealing an underlying molecular mechanism for ocular surface disorders.

#3001 MtDNA copy number correlates to coronary artery calcium score and biological age in kidney failure patients

Abstract Background and Aims Chronic kidney disease (CKD) and kidney failure are connected to increased oxidative stress and vascular calcification, which are indicators for development of comorbidities and mortality outcome. Mitochondrial (mt)DNA copy number has been reported as independent predictor for frailty and mortality outcome of various cardiovascular diseases (CVD) and cancer. We aimed that mtDNA copy number in whole blood of kidney failure patients can be correlated to coronary artery media calcification score and coronary artery calcium (CAC) score and be used as an independent predictor for comorbidities and mortality outcome. Method Quantitative PCR (qPCR) with TaqMan® probes for three mtDNA genes (mtND1, mtND4 and mtCOX1) and two single locus genes on nuclear DNA (hemoglobin subunit beta and 18S), for normalization, is performed on DNA samples isolated from collected blood of 196 kidney transplant donors and 211 recipients at basal timepoint and 32 at 1-year-follow-up timepoint, included in the KaroKidney biobank. Resulting mtDNA copy number is investigated for correlation to CAC score, patient mortality outcome, biological age determined by skin autofluorescence and other clinical parameters. Results In our Swedish kidney transplant cohort we can see statistically significant difference in mtDNA copy number between kidney failure patients (recipients) and healthy controls (donors). No obvious difference between females and males was observed. mtDNA copy number correlates to biological age determined by skin autofluorescence, CAC score and Framingham CVD risk score. In the 32 1-year-follow-up samples we could see significant increase/recovery of mtDNA copy number for male patients compared to their baseline before receiving a transplant. Conclusion In this study we show that mtDNA copy number in kidney failure patients correlates to biological age and CAC score, affirming mtDNA copy number as an independent predictor of frailty in this Swedish cohort of CKD patients. Additionally, we can see that a kidney transplant can lead to a significant increase of mtDNA copy number in blood one year later, suggesting a general increase in health quality.

#1868 Dapagliflozin reduces urinary kidney injury biomarkers in chronic kidney disease irrespective of albuminuria level

Abstract Background and Aims The beneficial effects of Sodium-Glucose Cotransporter 2(SGLT2) inhibitor in patients with chronic kidney disease (CKD) with low albuminuria levels have not been established. In this study, we aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. Method We prospectively enrolled healthy volunteers (HVs) (n = 20) and patients with CKD (n = 54) with and without diabetes mellitus (DM). Patients with CKD were divided into two subgroups by age- and sex-matched according to urinary albumin-creatinine ratio (uACR) levels (<300 mg/g and ≥300 mg/g). The CKD group received dapagliflozin 10 mg per day. Urine samples were collected before treatment and after 3 months and 6 months of dapagliflozin. Urinary kidney injury molecule-1 (KIM-1), interleukin-1β (IL-1β), and mitochondrial DNA nicotinamide adenine dinucleotide dehydrogenase subunit-1 (mtND1) copy number were measured. Results The estimated glomerular filtration rate (eGFR) of patients with CKD was lower than that of HVs (p < 0.001). During the study period, eGFR decreased and uACR did not change in the CKD group. Kidney injury markers were significantly elevated in patients with CKD compared with those in HVs. Dapagliflozin reduced urinary KIM-1, IL-1β and mtDNA copy number in patients with CKD after 6 months of treatment. In further, the levels of urinary KIM-1 and IL-1β, patients with CKD decreased after 6 months of dapagliflozin treatment regardless of albuminuria level. Conclusion In this study, dapagliflozin reduced urinary kidney injury biomarkers in patients with CKD, regardless of albuminuria level. These findings suggest that SGLT2i may also attenuate the progression of low albuminuric CKD.

Association between mitochondrial DNA genotype and sperm motility in humans

The relationship between genetic alterations in mitochondrial DNA (mtDNA) and progressive motility (PR) and rapid progressive motility (grade A) of ejaculated human spermatozoa remains unclear. In this study, we explored the association between human mtDNA genotype and sperm PR and grade A by analyzing mtDNA copy number, loci, haplogroup, rearrangement, deletions, and duplications and sperm motility parameters. Human sperm mtDNA copy number, loci and haplogroups were not associated with human sperm motility PR or A grade. However, the cumulative frequency of human sperm mtDNA rearrangements (including deletions and duplications) in participants with high PR and grade A ratio was higher than in participants with low PR and grade A ratio. Additional studies are needed to understand the relationship between mtDNA genotypes, including deletions and duplications, and human sperm motility.

Impact of telomere length and mitochondrial DNA copy number variants on survival of newborn cloned calves

An established technology to create cloned animals is through the use of somatic cell nuclear transfer (SCNT), in which reprogramming the somatic cell nucleus to a totipotent state by enucleated oocyte cytoplasm is a necessary process, including telomere length reprogramming. The limitation of this technology; however, is that the live birth rate of offspring produced through SCNT is significantly lower than that of IVF. Whether and how telomere length play a role in the development of cloned animals is not well understood. Only a few studies have evaluated this association in cloned mice, and fewer still in cloned cows. In this study, we investigated the difference in telomere length as well as the abundance of some selected molecules between newborn deceased cloned calves and normal cows of different ages either produced by SCNT or via natural conception, in order to evaluate the association between telomere length and abnormal development of cloned cows. The absolute telomere length and relative mitochondrial DNA (mtDNA) copy number were determined by real-time quantitative PCR (qPCR), telomere related gene abundance by reverse-transcription quantitative PCR (RT-qPCR), and senescence-associated β-galactosidase (SA-β-gal) expression by SA-β-gal staining. The results demonstrate that the newborn deceased SCNT calves had significantly shortened telomere lengths compared to newborn naturally conceived calves and newborn normal SCNT calves. Significantly lower mtDNA copy number, and significantly lower relative abundance of LMNB1 and TERT, higher relative abundance of CDKN1A, and aberrant SA-β-gal expression were observed in the newborn deceased SCNT calves, consistent with the change in telomere length. These results demonstrate that abnormal telomere shortening, lower mtDNA copy number and abnormal abundance of related genes were specific to newborn deceased SCNT calves, suggesting that abnormally short telomere length may be associated with abnormal development in the cloned calves.

Mitochondrial DNA: Inherent Complexities Relevant to Genetic Analyses.

Mitochondrial DNA (mtDNA) exhibits distinct characteristics distinguishing it from the nuclear genome, necessitating specific analytical methods in genetic studies. This comprehensive review explores the complex role of mtDNA in a variety of genetic studies, including genome-wide, epigenome-wide, and phenome-wide association studies, with a focus on its implications for human traits and diseases. Here, we discuss the structure and gene-encoding properties of mtDNA, along with the influence of environmental factors and epigenetic modifications on its function and variability. Particularly significant are the challenges posed by mtDNA's high mutation rate, heteroplasmy, and copy number variations, and their impact on disease susceptibility and population genetic analyses. The review also highlights recent advances in methodological approaches that enhance our understanding of mtDNA associations, advocating for refined genetic research techniques that accommodate its complexities. By providing a comprehensive overview of the intricacies of mtDNA, this paper underscores the need for an integrated approach to genetic studies that considers the unique properties of mitochondrial genetics. Our findings aim to inform future research and encourage the development of innovative methodologies to better interpret the broad implications of mtDNA in human health and disease.

Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress.

The new topical formula is urgent needed to meet clinical needs for majority mild patients with psoriasis. Deucravacitinib exerts outstanding anti-psoriatic capacity as an oral TYK2 inhibitor; however, single therapy is insufficient to target the complicated psoriatic skin, including excessive reactive oxygen species (ROS) and persistent inflammation. To address this need, engineered smart nano-therapeutics hold potential for the topical delivery of deucravacitinib. hydrophobic Deucravacitinib was loaded into polyethylene glycol block-polypropylene sulphide (PEG-b-PPS) for transdermal delivery in the treatment of psoriasis. The oxidative stress model of HaCaT psoriasis was established by TNF-α and IL-17A in vitro. JC-1 assay, DCFH-DA staining and mtDNA copy number were utilized to assess mitochondrial function. 0.75% Carbopol®934 was incorporated into SPMs to produce hydrogels and Rhb was labeled to monitor penetration by Immunofluorescence. In vivo, we established IMQ-induced psoriatic model to evaluate therapeutic effect of Car@Deu@PEPS. Deu@PEPS exerted anti-psoriatic effects by restoring mitochondrial DNA copy number and mitochondrial membrane potential in HaCaT. In vivo, Car@Deu@PEPS supramolecular micelle hydrogels had longer retention time in the dermis in the IMQ-induced ROS microenvironment. Topical application of Car@Deu@PEPS significantly restored the normal epidermal architecture of psoriatic skin with abrogation of splenomegaly in the IMQ-induced psoriatic dermatitis model. Car@Deu@PEPS inhibited STAT3 signaling cascade with a corresponding decrease in the levels of the differentiation and proliferative markers Keratin 17 and Cyclin D1, respectively. Meanwhile, Car@Deu@PEPS alleviated IMQ-induced ROS generation and subsequent NLRP3 inflammasome-mediated pyroptosis. Deu@PEPS exerts prominent anti-inflammatory and anti-oxidative effects, which may offers a more patient-acceptable therapy with fewer adverse effects compared with oral deucravacitinib.

Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis

ObjectivesNeutrophil extracellular trap formation and cell-free DNA (cfDNA) contribute to the inflammation in rheumatoid arthritis (RA), but it is unknown if mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) is more abundant in the circulation. It is unclear if DNA concentration measurements may assist in clinical decision-making.MethodsThis single-center prospective observational study collected plasma from consecutive RA patients and healthy blood donors. Platelets were removed, and mtDNA and nDNA copy numbers were quantified by polymerase chain reaction (PCR).ResultsOne hundred six RA patients and 85 healthy controls (HC) were recruited. Circulating median mtDNA copy numbers were increased 19.4-fold in the plasma of patients with RA (median 1.1 x108 copies/mL) compared to HC (median 5.4 x106 copies/mL, p<0.0001). Receiver operating characteristics (ROC) curve analysis of mtDNA copy numbers identified RA patients with high sensitivity (92.5%) and specificity (89.4%) with an area under the curve (AUC) of 0.97, p <0.0001 and a positive likelihood ratio of 8.7.Demographic, serological (rheumatoid factor (RF) positivity, anti-citrullinated protein antibodies (ACPA) positivity) and treatment factors were not associated with DNA concentrations. mtDNA plasma concentrations, however, correlated significantly with disease activity score-28- erythrocyte sedimentation rate (DAS28-ESR) and increased numerically with increasing DAS28-ESR and clinical disease activity index (CDAI) activity. MtDNA copy numbers also discriminated RA in remission (DAS28 <2.6) from HC (p<0.0001). Also, a correlation was observed between mtDNA and the ESR (p = 0.006, R= 0.29). Similar analyses showed no significance for nDNA.ConclusionIn contrast to nDNA, mtDNA is significantly elevated in the plasma of RA patients compared with HC. Regardless of RA activity, the abundance of circulating mtDNA is a sensitive discriminator between RA patients and HC. Further validation of the diagnostic value of mtDNA testing is required.

Single-cell mtDNA dynamics in tumors is driven by coregulation of nuclear and mitochondrial genomes.

The extent of cell-to-cell variation in tumor mitochondrial DNA (mtDNA) copy number and genotype, and the phenotypic and evolutionary consequences of such variation, are poorly characterized. Here we use amplification-free single-cell whole-genome sequencing (Direct Library Prep (DLP+)) to simultaneously assay mtDNA copy number and nuclear DNA (nuDNA) in 72,275 single cells derived from immortalized cell lines, patient-derived xenografts and primary human tumors. Cells typically contained thousands of mtDNA copies, but variation in mtDNA copy number was extensive and strongly associated with cell size. Pervasive whole-genome doubling events in nuDNA associated with stoichiometrically balanced adaptations in mtDNA copy number, implying that mtDNA-to-nuDNA ratio, rather than mtDNA copy number itself, mediated downstream phenotypes. Finally, multimodal analysis of DLP+ and single-cell RNA sequencing identified both somatic loss-of-function and germline noncoding variants in mtDNA linked to heteroplasmy-dependent changes in mtDNA copy number and mitochondrial transcription, revealing phenotypic adaptations to disrupted nuclear/mitochondrial balance.

Mitochondrial DNA control of gene expression and cell function in HeLa cybrids of HeLa ρ0 cells with transferred mtDNA of A549 cells

Asthma is a disease characterized by airway inflammation and hyperreactivity. Mitochondria have their own DNA (mtDNA) that encodes essential components of Electron Transport Chain complexes and is inherited exclusively maternally. Variants in mtDNA (haplogroups) are linked to risks and severity of other diseases but have not been studied in asthma. We hypothesized that mitochondrial genome can regulate expression of nDNA genes important in asthma pathophysiology. Haplogroup H mtDNA from A549 lung epithelial cells was transferred to mtDNA-deleted HeLa cells (ρ0) to create HeLa[H] cybrids that have identical nuclei but varied mitochondrial genome as compared to HeLa cells with haplogroup L mtDNA. Cells were analyzed for mtDNA copy number by quantitative polymerase chain reaction (qPCR), energy metabolism by monitoring the cellular respiration and glycolysis using Seahorse analyzer, and mtDNA sequencing for haplogroup. Single-cell RNA sequencing technology, SeqGeq bioinformatics program, and western blot were used to analyze differential gene expression and involved pathways among these cells. ρ0 cells have mtDNA copy number &lt;1, while cybrids have mtDNA copy number similar to A549 cells and different from HeLa cells {mtDNA copy number (mean±SD), HeLa 636±115, ρ0 0.13±0.08, cybrid 1956±354, A549 1738±504, n≥2 replicate experiments, ANOVA p&lt;0.001}. ρ0 have no mitochondrial oxygen consumption and maintain energy generation by increased glycolysis, whereas cybrids have similar oxygen consumption and glycolytic rates to HeLa and A549 {mitochondrial basal oxygen consumption pmole/min/mg protein (mean±SD), HeLa 7.78±0.43, ρ0 0.51±0.56, cybrid 6.76±2.34, A549 4.86±0.41, n≥3, ANOVA p&lt;0.001; glycolysis mpH/min/mg protein (mean±SD), HeLa 0.91±0.08, ρ0 1.96±0.16, cybrid 0.52±0.14, A549 0.72±0.48, n≥3, ANOVA p&lt;0.001}. Compared to HeLa, ρ0 cells lack expression of all 13 mtDNA-encoded proteins and have changes in nuclear-encoded DNA (nDNA) gene expression (4,047 nDNA up, and 5,552 nDNA down). Switching from L to H haplogroup results in greater changes in gene expression (9,320 nDNA up, 4,376 nDNA down, 9 mtDNA up, and 4 mtDNA down). Compared to HeLa, cybrids have greater expression of genes important in bioenergetics and asthma, i.e., TCA pathway genes (aconitase, isocitrate dehydrogenase, oxoglutarate dehydrogenase, succinate dehydrogenase), cytokines, and inducible NO synthase (iNOS) pathway genes. Overall, these studies suggest that mitochondria are not only important for energy generation but relevant to cell signaling, inflammation, and metabolism in asthma. This work is supported by the National Heart, Lung, and Blood Institute HL081064, HL103453. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Lower Mitochondrial Genome Turnover and Greater Mutation Frequency in Skeletal Muscle of Aged Compared to Adult OKC-HET Rats

Mitochondrial genomic integrity, which is supported by processes such as replication, repair, and turnover, is critical in supporting metabolism and organismal health. Accumulation of mitochondrial DNA (mtDNA) mutations contributes to mitochondrial and whole-tissue dysfunction, which lead to chronic diseases including sarcopenia. The underlying mechanisms that promote generation and age-related accumulation of mtDNA mutations are unclear. mtDNA mutants may have a replicative advantage over wild-type mtDNA that propagates the accumulation of mtDNA mutations with age. However, there is limited in vivo data regarding effects of age on mtDNA replication, particularly in skeletal muscle. We hypothesized mtDNA synthesis rates would increase with age as mutation burden increased in skeletal muscle in both male and female rats. Methods: We measured mtDNA synthesis over 14 days using the stable isotope tracer deuterium oxide (D2O) and assessed mtDNA copy number and mutation deletion frequency using digital PCR in quadriceps muscle of 9- and 26 month-old (mo) male and female OKC-HET rats, which have heterogenous mtDNA backgrounds. Results: There were no differences in mtDNA copy number between sexes or ages. However, 26 month-od rats had lower rates of mtDNA synthesis compared to 9 month-old rats (9 mo: 0.509 ± 0.009 %/day, 26 month: 0.371 ± 0.048 %/day; p=0.0024) and greater mtDNA half-lives (9 mo: 132 ± 1.79 days, 216 ± 25.63 days; p=0.0009). Concomitant with lower mtDNA synthesis, 26 month-old rats had greater (p=0.003) mtDNA deletion mutation frequency (2.023e-004 ± 7.18e-005) than 9 month-old rats (9.310e-005 ± 2.404e-005). 26 month-old female rats (1.309e-004 ± 2.386e-005) had a lower (p=0.008) mutation burden than male rats (2.74e-004 ± 4.484e-005). Conclusion: Contrary to our hypothesis, mtDNA synthesis declined with age as mutation burden increased in the quadriceps. Because mtDNA copy number was not different between ages, while synthesis decreased, mtDNA turnover declined with age. Altogether, these results suggest lower mtDNA turnover rates may contribute to age-related mtDNA mutation burden. Future studies should test how modulating mtDNA turnover affects mutation frequency and mitochondrial function. This study was supported by funding from NIH grants R21AG072137 and 5T32AG052363-04. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

The Dynamic Genome at Altitude: Mitochondrial DNA Copy Numbers in Acute and Chronic Hypoxia

Mitochondria contain a tiny circular DNA (mtDNA) that encodes components of the electron transport chain, including Complex IV, where over 95% of oxygen is consumed in the process of generating energy. Each mitochondrion contains tens to hundreds of copies of mtDNA, which decrease with aging and disease, but little is known regarding how mtDNA levels change in response to hypoxia. Here we compare samples with different durations and magnitudes of exposure to high-altitude hypoxia: Ethiopian Amhara with &gt;5000 years exposure and the potential for evolved adaptations, Ethiopian Oromo with ~500 years of generations of lifelong acclimatization, and acutely exposed European trekkers with 15 days of abrupt individual acclimatization followed by descent to baseline. Lowland natives of the same ethnicities provide unstressed reference samples. Our previous studies found that Amhara adapted to hypoxia through increased blood flow due to nitric oxide-mediated vasodilation, while Oromo have increased carrying capacity through elevated hemoglobin concentration. We measured mtDNA copy numbers relative to nuclear DNA (mtDNA-CN) in 326 healthy adults: 52 low-altitude Amhara at 1200 m, 113 high-altitude Amhara at 3700 m; 47 low-altitude Oromo at 1700 m, and 105 high-altitude Oromo at 4000 m; and 9 European lowlanders at a baseline of 1300 m, after ascent to 5050 m, and upon return to 1300 m. High-altitude Amhara had 21% higher median mtDNA-CN than their low-altitude counterparts (median (IQR): high-altitude, 363.0 (281.0–427.0); low-altitude, 299.0 (246.1–333.2); p&lt;0.0001), while high-altitude Oromo had 17% lower mtDNA-CN than their low-altitude counterparts (high-altitude, 236.7 (165.2–315.6); low-altitude, 283.7 (216.9–335.6); p=0.01). High-altitude Amhara had significantly higher median mtDNA-CN than high-altitude Oromo (p&lt;.0001). European lowlanders had 44% lower mtDNA-CN after an 13-day ascent to 5050 m (1300 m, 322.5 (262.8–356.4); 5050 m 180.9 (145.1–230.5); p=0.002) that returned to baseline (319.5 (247.3–267.6); p=0.5) after a 6-day descent to 1300 m. These findings further confirm variation in acute and chronic responses to hypoxia, within and across populations. These findings require validation and expansion to address the mechanisms connecting expression of mtDNA copy numbers to oxygen-requiring bioenergetics. This work is supported by the National Heart, Lung, and Blood Institute HL060917 and National Science Foundation BCS-0452326. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Cells expressing POLG loss-of-function variants can decrease mtDNA copy number and increased growth rates in neighbouring A7r5 and HeLa cells

Mitochondrial disfunction promotes vascular disease, and mitochondrial diseases offer valuable insights into the pathological mechanisms of mitochondrial dysfunction. We previously described a patient cohort with variants in the mitochondrial DNA gamma polymerase (POLG) that were prone hypertension. We hypothesized that the POLG variants promote hypertrophy or hyperplasia of vascular smooth muscle cells in a way that stiffens or thickens blood vessels to explain the high rate of resistant hypertension in this cohort. The objective of this study was to assess the cellular phenotype of cells over-expressing POLG variants: pathogenic Y955C and variants of unknown significance; R964C, I1098N, Y1138C. We transiently expressed human FLAG-tagged POLG variants in rat A7r5 and HeLa cells for 2-4 days. Transfection effciency ranged from 20-30% in A7r5 and &gt;60% in HeLa cells. POLG variants increased cell density by nuclear counting (20-60%) and growth rates measured by 48-72 h of live-cell imaging (Y955C &gt; R964C &gt; I1089N » Y1138C). Compared to wild-type, Y955C and R964C reduced mtDNA copy number (mCN) measured by droplet digital PCR by 10-20%. Imaging mtDNA nucleoids (anti-dsDNA) and the FLAG-tag showed that reduced mCN was not restricted to transfected cells. Addition of a P2A-T2A-nuclear-EGFP to the POLG constructs demonstrated that faster growth rates were not specific to transfected cells. Resting and oligomycin-stimulated mitochondrial membrane potential imaged with TMRM were unaffected by Y955C and R964C. Mitochondrial ROS (mitoSox) was similar between cultures transfected with Wild-type versus POLG variants and lower than levels stimulated by antimycin-A’s inhibition of complex III. Notably, we found a linear relationship between mCN and cell density that was not simply due to smaller cell size at higher densities. Using Hoescht-33342 staining to assess cell cycle, no clear difference in cell-cycle distribution was evident in unsynchronized cultures. We conclude that modest reduction of mCN induces a mitogenic effect, likely via a diffusible messenger that further reduces mCN in a cell population. The signalling mechanism of this phenomenon remains to be identified, but our results confirm that POLG malfunction can alter smooth muscle physiology in a way that could support pathogenic vascular remodelling and could promote enhanced growth in cancerous cells. Funded by the Natural Sciences and Research Council of Canada. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

BDNF/TrkB Induces pCREBS133 Phosphorylation and Activates Mitochondrial Biogenesis in Rat Phrenic Motor Neurons

Neural control of the diaphragm muscle (DIAm) is essential to sustain breathing. During breathing, fatigue resistant DIAm motor units are recruited comprising smaller phrenic motor neurons (PhMNs) and type I and IIa muscle fibers. Larger PhMNs comprise more fatigable DIAm motor units that are infrequently active during expulsive behaviors. The difference in activation history is reflected in the higher mitochondrial volume density in smaller PhMNs. In PhMNs, brain-derived neurotrophic factor (BDNF) signals through its high-affnity receptor, tropomyosin receptor kinase B (TrkB.FL). Previously, we found that intrathecal BDNF treatment induces CREB phosphorylation at Serine 133 (pCREBs133). We hypothesized that pCREBs133 binds to the PGC1a promoter, transcriptionally targeting PGC1a expression, mediating downstream increased expression of NRF1, NRF2, and TFAM and mitochondrial biogenesis. To test this hypothesis, we used a chemosensitive TrkBF616 rat model with a knock-in allele sensitive to 1NMPP1 in that TrkB kinase is inhibited following 1NMPP1, a small molecule derivative of the protein kinase inhibitor protein phosphatase 1 that plays a significant role inhibiting the TrkB phosphorylation and activation. Systemic treatment of 1NMPP1 in TrkBF616 rats inhibits TrkB kinase activity. A bioinformatic analysis was performed to identify a putative binding site for pCREBs133 in the PGC1a promoter sequence in rats. Using a chromatin immunoprecipitation (ChIP) assay we found that pCREBS133 binds to the PGC1a promoter in rat cervical ventral horn. We showed that intrathecal BDNF treatment increased pCREBs133 phosphorylation, which was blocked by 1NMPP1 treatment in TrkBF616 rats. PGC1a, NRF1/2, and TFAM protein was compared in cervical ventral horn lysates from BDNF- and BDNF+1NMPP1-treated TrkBF616 rats by qRT-PCR and Western Blot. Relative mtDNA copy number (normalized to nuclear DNA) was quantified by qPCR to assess the mitochondrial biogenesis. All results were analyzed by paired t-test. Following 1NMPP1-induced inhibition of TrkB kinase, PGC1a, NRF1/2, and TFAM mRNA and protein expression was reduced. Consistent with these findings, mtDNA copy number was decreased following TrkB kinase inhibition by 1NMPP1. We conclude that inhibition of TrkB kinase by 1NMPP1 reduces PGC1a-mediated mitochondrial biogenesis in rat cervical ventral horn. Supported by NIH grants AG44615 and HL146114. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Abstract 3011: Parkin Mediated Mitophagy Deficiency In VSMCs Exacerbates Abdominal Aortic Aneurysm

Background: Parkin-mediated mitophagy eliminates dysfunctional mitochondria to reduce inflammatory responses caused by mtDAMPs. Given that reduced mitophagy is a hallmark of aging and AAA is an aging-associated disease, we sought to investigate the role of Parkin-mediated mitophagy in the development of AAAs. Methods: Groups of young (8-10 wks, n= 6/group) and aged (18-20 months, n=6/group) male Mito-QC mice either without intervention or underwent AAV.mPCSK9 D377Y infection and western diet feeding followed by Angiotensin II (AngII) or saline pump infusion for 28 days. Separately, young male Myh11-creER T2 Parkin fl/fl mice underwent tamoxifen (Parkin SMCKO) or vehicle injections (n=35-39/group), AAV.mPCSK9 D377Y infection, western diet feeding and AngII infusion. In vitro , MOVAs were treated with AngII and the USP30 inhibitor, a mitophagy enhancer, or vehicle followed by assessment of Parkin and mtROS. Results: VSMCs in aged Mito-QC mice, identified by a CD45 - CD90 - α-actin + profile, exhibit diminished mitophagy activity (p=0.017) and decreased Parkin expression (p=0.029). In young AAAs, VSMCs characterized as CD45 - CD90 - α-actin high and α-actin low also demonstrated decreased mitophagy (p=0.0017, p=0.0020), decreased Parkin(p=0.029), and a decreased trend in SDHB in Complex II (p=0.103) and NDUFB8 in Complex I (p=0.040) of the electron transport chain. Parkin SMCKO mice demonstrated increased AAA rupture (p=0.038), greater aneurysm size (p=0.044), reduced mtDNA copy numbers (p=0.026) and elevated mtROS compared to their controls. Parkin SMCKO mice demonstrated trends of diminished expression of respiratory complexes (p=0.070) and an exacerbated decrease in the maximal OCR involving both coupled and uncoupled activities of Complex I plus II (p=0.045, 0.028). In vitro experiments demonstrated treatment with the USP30 inhibitor reversed the reduction in mitophagy activity and mtROS increasement induced by AngII in MOVAS. Conclusions: In conclusion, mitophagy activity in aortic VSMCs and Parkin decreased with aging and separately, in AAAs and Parkin SMCKO mice, associated with exacerbation of AAA progression. These studies suggest stabilization of Parkin-dependent mitophagy could represent a novel AAA therapeutic target.

Cell-Free Hemoglobin Induces Vascular and Mitochondrial Dysfunction in the Pulmonary Endothelium in an Oxidation-State Dependent Manner

Background: Sepsis results in significant organ damage due in part to a breakdown in endothelial vascular function. Elevated levels of cell-free hemoglobin (CFH) drive endothelial dysfunction in the lungs. CFH generates reactive oxygen species (ROS) via the iron present in the heme moiety, which can be oxidized from ferrous (CFH2+) to ferric (CFH3+). Recent studies suggest mitochondrial dysfunction may be a key pathway leading to microvascular dysfunction. We hypothesize that CFH induces mitochondrial dysfunction and microvascular endothelial barrier disruption in the lung in an oxidative-state dependent manner. Methods: CFH was converted from CFH2+ to CFH3+ by UV irradiation (validated by spectrophotometry). Primary human lung microvascular endothelial cells (HLMVECs) were treated with 1.0 mg/mL CFH2+, CFH3+, or vehicle control. Barrier dysfunction was measured via electric cell-substrate impedance sensing (ECIS) and express permeability test (XPerT) at 24h. We quantified mitochondrial superoxide (MitoSOX Red; 5 uM) by flow cytometry (1, 6, 24h) and total cellular ROS production (CellROX Deep Red; 5 uM) by fluorescence microscopy (6 and 24 h). Mitochondrial morphology (electron density, roundness, area, circularity, and aspect ratio) was assessed by transmission electron micrographs at 6h and quantified by a blinded reviewer (ImageJ). Activation of the mitochondrial permeability transition pore (mPTP) was assessed by flow cytometry using calcein-AM with cobalt chloride. DNA was purified from patient plasma and the copy number of mitochondrial genes ND4L and CYB was quantified by digital droplet PCR. Results: In HLMVECs, CFH generated excess ROS (CellROX and MitoSOX) at 6h compared to vehicle (522 vs 265 MFI, p &lt; 0.01). Morphology analysis demonstrated increased electron density and aspect ratio and decreased circularity and roundness. mPTP activity was increased by CFH3+ (1295 vs 2197 MFI, p &lt; 0.01) compared to vehicle or CFH2+. Barrier dysfunction caused by CFH3+ measured by ECIS peaked at 6h (-1270 vs 262 max TER drop, p &lt; 0.0001), while XPerT confirmed dysfunction at 24h (9.41e+06 vs 6.53e+05 total fluorescent area, p &lt; 0.01). Quantification of mtDNA copy number in patient plasma revealed that circulating mt-ND4L copies correlate with CFH (r = 0.44, p &lt; 0.01). Conclusions: The results demonstrate significant perturbations to mitochondrial function and network dynamics caused by oxidized CFH (3+). The novel findings point towards the ferric (3+) form of hemoglobin as the primary driver of endothelial dysfunction, and the underlying mechanism is directly related to disruption of the mitochondrial network. The association of mitochondrial and vascular biomarkers demonstrates an urgent need to better understand how mitochondrial dysfunction can be prevented to limit vascular damage. This work was funded by the National Institutes of Health NHLBI 5R35HL150783 and 1F31HL167471. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Lack of detectable sex differences in the mitochondrial function of Caenorhabditis elegans

BackgroundSex differences in mitochondrial function have been reported in multiple tissue and cell types. Additionally, sex-variable responses to stressors including environmental pollutants and drugs that cause mitochondrial toxicity have been observed. The mechanisms that establish these differences are thought to include hormonal modulation, epigenetic regulation, double dosing of X-linked genes, and the maternal inheritance of mtDNA. Understanding the drivers of sex differences in mitochondrial function and being able to model them in vitro is important for identifying toxic compounds with sex-variable effects. Additionally, understanding how sex differences in mitochondrial function compare across species may permit insight into the drivers of these differences, which is important for basic biology research. This study explored whether Caenorhabditis elegans, a model organism commonly used to study stress biology and toxicology, exhibits sex differences in mitochondrial function and toxicant susceptibility. To assess sex differences in mitochondrial function, we utilized four male enriched populations (N2 wild-type male enriched, fog-2(q71), him-5(e1490), and him-8(e1498)). We performed whole worm respirometry and determined whole worm ATP levels and mtDNA copy number. To probe whether sex differences manifest only after stress and inform the growing use of C. elegans as a mitochondrial health and toxicologic model, we also assessed susceptibility to a classic mitochondrial toxicant, rotenone.ResultsWe detected few to no large differences in mitochondrial function between C. elegans sexes. Though we saw no sex differences in vulnerability to rotenone, we did observe sex differences in the uptake of this lipophilic compound, which may be of interest to those utilizing C. elegans as a model organism for toxicologic studies. Additionally, we observed altered non-mitochondrial respiration in two him strains, which may be of interest to other researchers utilizing these strains.ConclusionsBasal mitochondrial parameters in male and hermaphrodite C. elegans are similar, at least at the whole-organism level, as is toxicity associated with a mitochondrial Complex I inhibitor, rotenone. Our data highlights the limitation of using C. elegans as a model to study sex-variable mitochondrial function and toxicological responses.